BioWorld

Feb. 22, 2007

View Archived Issues

Other News To Note

Read More

Appointments And Advancements

Read More

TransTech Acquires Entire GKA Program In Diabetes From Novo

TransTech Pharma Inc. reacquired all rights to a glucokinase activator program that it had partnered with Novo Nordisk A/S more than five years ago, increasing an already healthy pipeline in the area of diabetes. (BioWorld Today) Read More

FDA Decides Against Reviewing Pharmacyclics' NDA For Xcytrin

Read More

Dyax Regains All DX-88 Rights, $17M; Ends JV With Genzyme

Read More

CoDa Raises $20M Series A For Wound Healer Nexagon

Read More

Access Adding Cancer Products Though Acquisition Of Somanta

Read More

Clinic Roundup

Read More